Latest Octreotide Stories
Combination treatment with everolimus, an inhibitor of the mammalian target rapamycin (mTOR), and octreotide has shown to improve progression-free survival for patients with advanced neuroendocrine tumors and a history of carcinoid syndrome.
NEW YORK and JERUSALEM, June 6, 2011 /PRNewswire/ -- Chiasma, Inc., a privately held biopharma company, presented pharmacology results from clinical studies at the 12th International Pituitary Congress showing that Octreolin, a proprietary investigational new oral formulation of octreotide, demonstrated a consistent pharmacokinetic (PK) profile similar to that of subcutaneously injected octreotide acetate.
PITTSBURGH, April 5, 2011 /PRNewswire/ -- Mylan Inc.
- Small missiles, especially grape, canister, fragments of iron, and the like, when fired, as upon an enemy at close quarters.
- To fire mitraille at.